Search clinical trials for: Liraglutide - Placebo

Total 53781 results

Novo Nordisk A/S

Completed

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy (DUAL™ III)

Diabetes Mellitus, Type 2 | Diabetes

United States, Slovakia, Hungary, France, Australia
Texas Tech University
Novo Nordisk A/S

Completed

To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity

Obesity

United States
Novo Nordisk A/S

Completed

Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Poland, United Kingdom, Denmark, France, Austria, Czech Republic, Australia
Kelly Allison
Novo Nordisk A/S

Terminated

Binge Eating Liraglutide Intervention (BELIEVE)

Binge-Eating Disorder

United States
Novo Nordisk A/S

Completed

Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

India, Korea, Republic of, China
Novo Nordisk A/S

Completed

Comparison of Two Liraglutide Formulations in Healthy Volunteers

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

In-market Utilisation of Liraglutide Used for Weight Management in Europe

Obesity | Metabolism and Nutrition Disorder

Italy, Germany
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Comparison of Three Liraglutide Formulations in Healthy Volunteers

Healthy | Diabetes

Australia
Novo Nordisk A/S

Completed

Comparison of Two Liraglutide Formulations in Healthy Subjects

Healthy | Diabetes

Sweden
Novo Nordisk A/S

Completed

Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers

Healthy | Diabetes

Sweden
St Vincent's University Hospital, Ireland
University College Dublin; Health Research Board, Ireland

Completed

Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

Sleep Apnea, Obstructive

Ireland
Novo Nordisk A/S

Completed

Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark, Sweden, United Kingdom, Norway
Novo Nordisk A/S

Completed

Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes (ROOTS)

Diabetes Mellitus, Type 2 | Diabetes

Belgium
Novo Nordisk A/S

Completed

Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function

Diabetes Mellitus, Type 2 | Diabetes

Australia
Novo Nordisk A/S

Completed

Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together (LEAD-2)

Diabetes Mellitus, Type 2 | Diabetes

Slovakia, India, Italy, Russian Federation, Spain, Denmark, United Kingdom, Sweden, Belgium, Ireland, Argentina, Hungary, Norway, South Africa, Germany, Croatia, Netherlands, Bulgaria, Australia, Romania
Chen Wei Ren, MD

Unknown

Effects of Glucagon Like Peptide-1 on No-reflow

Acute ST-segment Elevation Myocardial Infarction

China
Novo Nordisk A/S

Completed

Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice

Diabetes Mellitus, Type 2 | Diabetes

Italy
Novo Nordisk A/S

Completed

Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of
Novo Nordisk A/S

Completed

A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers

Obesity | Metabolism and Nutrition Disorder

Netherlands
Novo Nordisk A/S

Completed

Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes (EVIDENCE)

Diabetes Mellitus, Type 2 | Diabetes

France
Novo Nordisk A/S

Completed

Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark, Netherlands, France, Slovakia
Novo Nordisk A/S

Completed

A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India (Lead-In)

Diabetes Mellitus, Type 2 | Diabetes

India
Novo Nordisk A/S

Completed

Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors

Obesity | Metabolism and Nutrition Disorder

Germany
Novo Nordisk A/S

Completed

Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

Diabetes Mellitus, Type 2 | Diabetes

Spain, Germany, France, United Kingdom
Novo Nordisk A/S

Completed

Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Peter Rossing
Novo Nordisk A/S

Completed

Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes (Liratime)

Type 2 Diabetes

Denmark
Woman's
Novo Nordisk A/S

Completed

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

Type 2 Diabetes Mellitus | Metabolic Syndrome | Impaired Glucose Tolerance | Gestational Diabetes Mellitus | Disorder of Glucose Regulation

United States
Haugaard, Steen Bendix, M.D., DMSc

Completed

The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes (AddHope2)

Coronary Artery Disease | Diabetes Mellitus, Type 2

Denmark
Novo Nordisk A/S

Completed

Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function

Diabetes Mellitus, Type 2 | Diabetes

Poland
VectivBio AG

Completed

Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation

Healthy Subjects

Netherlands
VectivBio AG

Active, not recruiting

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF (STARS)

Short Bowel Syndrome

United States, France, United Kingdom, Israel, Korea, Republic of, Germany, Japan, Taiwan, Sweden, Belgium, Spain, Czechia, Hungary, Norway, Italy, Argentina, Denmark, Poland
VectivBio AG

Completed

Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.

Chronic Kidney Disease

United States
Unidad de Cirugia Bariatrica Hospital Civil Dr....

Completed

Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery

Weight Loss | Obesity, Morbid | Bariatric Surgery Candidate

Mexico
Novo Nordisk A/S

Completed

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

Diabetes Mellitus, Type 2 | Diabetes

Germany
Radboud University Medical Center

Unknown

Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes (ELEGANT)

Type 2 Diabetes Mellitus

Netherlands
Milton S. Hershey Medical Center
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)

Completed

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Opioid-Related Disorders | Opiate Substitution Treatment

United States
Hadassah Medical Organization

Unknown

GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients

Uncontrolled Type 1 Diabetic Patients
Novo Nordisk A/S

Completed

Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients

Obesity

Mexico
Novo Nordisk A/S

Completed

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes (Lead-Ph)

Diabetes Mellitus, Type 2 | Diabetes

Philippines
Novo Nordisk A/S

Completed

Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Spanish Cooperative Group for the Treatment of...

Terminated

Axitinib as Maintenance Treatment in Patients With Metastatic CRC (TTD-11-01)

Colorectal Carcinoma

Spain
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. (DUAL™ I Japan)

Diabetes Mellitus, Type 2 | Diabetes

Japan

3

Subscribe